Eli Lilly and Company
FDA Approves Lilly's ZYPREXA RELPREVV for Treatment of Schizophrenia in Adults
Published in Medical Letter on the CDC and FDA, January 3rd, 2010
Different from both oral and injected short-acting formulations, long-acting formulations of antipsychotics allow for stable concentrations of the active drug to remain at a therapeutic range for an extended period of time.(i)
"Patients, families and communities often needlessly suffer the consequences of relapse when daily...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Burness Communications
New research backs FDA ban on flavored cigarettes - Alzheimer Disease
New Alzheimer disease research from P.R. Solomon et al outlined - Bioartificial Liver
Study findings from B. Carpentier et al broaden understanding of bioartificial liver - Cardium Therapeutics
Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabetic Patients - Combination Therapy
New Indication for Procoralan(R): Use in Combination With Beta Blockers for Chronic Stable Angina Patients - Cubist Pharmaceuticals, Inc.
Trial Date Set for CUBICIN(R) Patent Litigation - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
